Please assess the completion status of the following clinical trial:

Trial Title: A Pharmacodynamic/Pharmacokinetic Study to Determine the Onset of Analgesic Effect and Plasma Levels of Tramadol in Patients With Acute Low Back Pain Receiving a Single 200 mg Dose of Tramadol Contramid® Once-a-Day

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females in generally good health aged 18-80 years with acute low back pain are eligible for this study.~* Patients must have pain of moderate to severe intensity on the patient rating of pain intensity scale without analgesia.~* Oral and written language comprehension at a level sufficient to comply with the protocol and complete study-related materials.~* Must have signed and dated an REB-approved written Informed Consent form which was also signed and dated by the Investigator prior to study participation.~Exclusion Criteria:~* Known history or symptoms suspicious of:~  * Spinal fracture~ * Cancer (i.e. constitutional symptoms such as recent unexplained chills or weight loss)~ * Spinal infection (e.g. IV drug abuse, immunosuppression)~* Cauda equina syndrome~* Spina bifida~* Foot drop~* Spinal surgery within 1 year of study entry~* Body Mass Index (BMI) \> 37~* Continuous chronic back pain~* More severe pain in a region other than the lower back~* Treatment of the back pain with non-pharmacological therapy (e.g. acupuncture chiropractic adjustment, Transcutaneous Electrical Nerve Stimulation, physiotherapy etc.) in the 3 weeks prior to study entry~* Use of any sedative hypnotics, topical preparations/medications and anaesthetics or muscle relaxants within 5 half-lives of the dose of study medication~* Use of any analgesic within 6 hours of the dose of study medication. In rare cases, if a patient is in moderate to severe pain despite having taken a short-acting analgesic and if at least 2 hours have passed since the dose of short-acting analgesic, the patient may be entered.~* A major illness, requiring hospitalisation during the 3 months before commencement of the screening period~* Unwillingness to stop taking pain medication other than the study medication~* Previous failure of treatment with tramadol or discontinuation of treatment with tramadol due to adverse events~* Treatment within the last 3 weeks with any of the following medications: monoamine oxidase inhibitors; tricyclic antidepressants and other tricyclic compounds (e.g. cyclobenzaprine, promethazine); neuroleptics; selective serotonin reuptake inhibitors (SSRIs); serotonin-norepinephrine reuptake inhibitors (SNRIs) or any other drug that reduces seizure threshold~* Treatment with another investigational agent within the last 30 days~* History of seizure disorder other than Infantile Febrile Seizures~* Previous or current opioid dependency~* Bowel disease causing malabsorption~* Pregnant or lactating women~* Known significant liver disease or symptoms of significant liver disease~* Known significant renal disease or symptoms of significant renal disease~* Current or past substance abuse or dependence, other than nicotine~* Allergy to tramadol or any structurally similar drugs (e.g. opiates)~* Any other condition that, in the opinion of the Investigators, would adversely affect the patient's ability to complete the study or its measures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Tramadol Contramid® OAD 200mg (Type: EXPERIMENTAL): 1 Tramadol Contramid® OAD 200mg tablet daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).